Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2007-08-21
2007-08-21
Weber, Jon (Department: 1653)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S003100, C514S021800, C530S308000, C530S324000, C424S198100, C424S278100
Reexamination Certificate
active
10091258
ABSTRACT:
The present invention relates to methods of treating intermittent claudication comprising administering glucagon-like peptide-1 (GLP-1) molecules to subjects suffering therefrom.
REFERENCES:
patent: 4196196 (1980-04-01), Tiholiz
patent: 5955594 (1999-09-01), Mishra
patent: 6107329 (2000-08-01), Hoover et al.
patent: 0708179 (1996-04-01), None
patent: WO94/15925 (1994-07-01), None
patent: WO98/08531 (1998-03-01), None
patent: WO98/08531 X (1998-03-01), None
patent: WO98/08873 (1998-03-01), None
patent: WO98/30231 (1998-07-01), None
patent: WO98/43658 (1998-10-01), None
patent: WO 00/16796 (2000-03-01), None
patent: WO 16797 (2000-03-01), None
Sterre, V. et al. (1998) Exendin-(9-39) is an inverse agonist of the murine glucagon-like peptide-1 receptor: implications for basal intracellular cyclic adenosine 3′,5′-monophosphate levels and beta-cell glucose competence. Endocrinol. vol. 139, 4448-4454.
Apstein, “Glucose-Insulin-Potassium for Acute Myocardial Infarction; Remarkable Results From a New Prospective, Randomized Trial,” CIRCULATION, vol. 98, Nov. 24, 1998, pp. 2223-2226; XP000960510 (no copy).
Jeffrey I. Weitz, John Byrne, G. Patrick Clagett, Michael E. Farkouh, John M. Porter, David L. Sackett, D. Eugene Strandness, Jr., Lloyd M. Taylor; “Diagnosis and Treatment of Chronic Arterial Insufficiency of the Lower Extremities: A Critical Review”;American Heart Association; 1996, pp. 1-43; Dallas, TX.
Simon Green; “Phosphorus 31 nuclear magnetic resonance spectroscopy suggests a mitochondrial defect in claudicating skeletal muscle”;Journal of Vascular Surgery; May 2001, vol. 33, No. 5, pp. 1-2, Mosby.
Muredach P. Reilly and Emile R. Mohler III; “Cilostazol: Treatment of Intermittent Claudication”;The Annals of Pharmacotherapy; Jan. 2001, vol. 35, pp. 48-56.
Carlos Iribarren, Andrew J. Karter, Alan S. Go, Assiamira Ferrara, Jennifer Y. Liu, Stephen Sidney and Joseph V. Selby; “Glycemic Control and Heart Failure Among Adult Patients With Diabetes”;American Heart Association; 2001, pp. 2668-2673; American Heart Association, Inc.
Hari K. Bhat, William R. Hiatt, Charles L. Hoppel, Eric P. Brass; “Skeletal Muscle Mitochondrial DNA Injury in Patients With Unilateral Peripheral Arterial Disease”;American Heart Association, Inc., 1999, pp. 807-812; American Heart Association, Inc.
Robert D. Abbott, Richard P. Donahue, William B. Kannel, Peter W.F. Wilson; “the Impact of Diabetes on Survival Following Myocardial Infarction in Man vs. Woman”;JAMA, Dec. 16, 1988, vol. 260, No. 23, pp. 3456-3460; National Heart, Lung and Blood Institute, Bethesda, MD.
Frederick N. Brand, Robert D. Abbott, and William B. Kannel; “Diabetes, Intermittent Claudication, and Rick of Cardiovascular Events”; Jul. 1988;Diabetes, vol. 38, pp. 504-509; National Heart Lung and Blood Institute, Bethesda, Maryland.
R. Stuart Gray, Richard R. Fabsitz, Linda D. Cowan, Elisa T. Lee, Barbara V. Howard and Peter J. Savage; “Risk Factor Clustering in the Insulin Resistance Syndrome”;American Journal of Epidemiology; 1998, vol. 148, No. 9, pp. 869-878, The Johns Hopkins University School of Hygiene and Public Health.
David L. Dawson, Bruce S. Cutler, William R. Hiatt, Robert W. Hobson II, John D. Martin, Enoch B. Bortey, William P. Forbers, and D. Eugene Strandness, Jr.; “A Comparison of Cilostazol and Pentoxifylline for Treating Intermittent Claudication”; 2000, pp. 523-530; by Excerpta Medica, Inc.
William R. Hiatt, Dilsher Nawaz, and Eric P. Brass; “Carnitine metabolism during exercise in patients with peripheral vascular disease”; 1987; pp. 2383-2387;The American Physiological Society; Colorado School of Medicine, Denver, Co.
Thomas L. Clanton and Paul F. Klawitter, “Physiological and Genomic Consequences of Intermittent Hypoxia Invited Review; Adaptive responses of skeletal muscle to intermittent hypoxia: the known and the unknown”; 2001;The American Physiological Society; pp. 2476-2487; The American Physiological Society.
M.D. Boska, J.A. Nelson N. Sripathi, I.I. Pipinos, A.D. Shepard, and K.M.A. Welch; “P MRS Studies of Exercising Human Muscle at High Temporal Resolution”; 1999, pp. 1145-1151, Wiley-Liss, Inc.
Robert L. Dupont, Keith E. Saylor; “Marijuana and Benzodiazepines in Patients Receiving Methadone Treatment”;JAMAJun. 1989, vol. 261, No. 23; pp. 3409; Institute for Behavior and Health, Inc.
Robert Matz; “Does Control of Diabetes Prevent Vascular Complications?”;JAMA; Jun. 1989, vol. 261, No. 23, p 3409; Institute for Behavior and Health, Inc.
Norman J. Sissman, Robert Wood Johnson; Patent Ductus Arteriosus, Prematurity, and Respiratory Distress Syndrome;JAMA, Jun. 1989, vol. 261, No. 23, p. 3410; University of Medicine and Dentistry of New Jersey, New Brunswick, NJ.
J.F. Scott, C.S. Gray, J.E. O'Connell and K.G.M.M. Alberti; “Glucose and insulin therapy in acute stroke; why delay further?”;QJM, 1998; 91:511-515.
Partial European Search Report dated Jan. 13, 2005 issued in European Patent Application No. 04027507.5.
Diaz, Rafael, et al, “Metabolic Modulation of Acute Myocardial Infarction the ECLA Glucose-Insulin-Potassium Pilot Trial,”, Circulation (1998) pp. 2227-2234, 98.
Ryan, Thomas J., et al, “ACC/AHA Guidelines for the Management of Patients with Acute Myocardial Infarction” J. Am Coll. Cardiol. (1996) pp. 1328-1428, 28.
Voll, C.L., et al. “Postischemic Insulin Reduces Spatial Learning Deficit Following Transient Forebrain in Ischemia Rats”, Stroke (1998) pp. 646-651, 20.
Coolidge Thomas R.
Hathaway David R.
Amylin Pharmaceuticals Inc.
Liu Samuel W.
Weber Jon
LandOfFree
Compositions and methods for treating peripheral vascular... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compositions and methods for treating peripheral vascular..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compositions and methods for treating peripheral vascular... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3862418